drugset
drugset / Trial / NCT06501066

Mesenchymal Stem Cells for Frailty Syndrome

NCT06501066 ↗

Phase 1/2 Active not recruiting 66 enrolled Meribank Biotech Co., Ltd.
RandomizedSequentialSingle-blindTreatment

Summary

This Phase I/II study is designed to evaluate the efficacy and safety of UMC119-06-05, an allogeneic umbilical cord mesenchymal stem cells, in older adults with frailty syndrome. This study will also seek to determine the long-term safety and clinical outcomes of UMC119-06-05 in subjects with frailty syndrome, which will provide information for subsequent clinical trials with UMC119-06-05.

Timeline

Start
2024-06-03
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+08 cells Intravenous

Indications

No indication recorded.